These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 19336745)

  • 1. Quantitative risk stratification in Markov chains with limiting conditional distributions.
    Chan DC; Pollett PK; Weinstein MC
    Med Decis Making; 2009; 29(4):532-40. PubMed ID: 19336745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of a microvolt T-wave alternans screening strategy for implantable cardioverter-defibrillator placement in the MADIT-II-eligible population.
    Chan PS; Stein K; Chow T; Fendrick M; Bigger JT; Vijan S
    J Am Coll Cardiol; 2006 Jul; 48(1):112-21. PubMed ID: 16814657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic disease projections in heterogeneous ageing populations: approximating multi-state models of joint distributions by modelling marginal distributions.
    Hoogenveen RT; van Baal PH; Boshuizen HC
    Math Med Biol; 2010 Mar; 27(1):1-19. PubMed ID: 19516046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs and clinical outcomes of primary prophylaxis of variceal bleeding in patients with hepatic cirrhosis: a decision analytic model.
    Saab S; DeRosa V; Nieto J; Durazo F; Han S; Roth B
    Am J Gastroenterol; 2003 Apr; 98(4):763-70. PubMed ID: 12738453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing the start time of statin therapy for patients with diabetes.
    Denton BT; Kurt M; Shah ND; Bryant SC; Smith SA
    Med Decis Making; 2009; 29(3):351-67. PubMed ID: 19429836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heart failure disease management programs: a cost-effectiveness analysis.
    Chan DC; Heidenreich PA; Weinstein MC; Fonarow GC
    Am Heart J; 2008 Feb; 155(2):332-8. PubMed ID: 18215605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regionalization of treatment for subarachnoid hemorrhage: a cost-utility analysis.
    Bardach NS; Olson SJ; Elkins JS; Smith WS; Lawton MT; Johnston SC
    Circulation; 2004 May; 109(18):2207-12. PubMed ID: 15117848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of categorizing continuous variables in decision-analytic models.
    Bentley TG; Weinstein MC; Kuntz KM
    Med Decis Making; 2009; 29(5):549-56. PubMed ID: 19596867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis.
    Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
    Cancer; 2006 Jun; 106(12):2576-82. PubMed ID: 16703595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incorporating dose-rate effects in Markov radiation cell survival models.
    Sachs RK; Hlatky L; Hahnfeldt P; Chen PL
    Radiat Res; 1990 Nov; 124(2):216-26. PubMed ID: 2247602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decision analysis and Markov modeling in urology.
    Hsieh MH; Meng MV
    J Urol; 2007 Nov; 178(5):1867-74. PubMed ID: 17868735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating the ratios of the stationary distribution values for Markov chains modeling evolutionary algorithms.
    Mitavskiy B; Cannings C
    Evol Comput; 2009; 17(3):343-77. PubMed ID: 19708772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting outcomes in cardiac surgery: risk stratification matters?
    Dupuis JY
    Curr Opin Cardiol; 2008 Nov; 23(6):560-7. PubMed ID: 18830070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multistate Markov chain model for longitudinal, categorical quality-of-life data subject to non-ignorable missingness.
    Cole BF; Bonetti M; Zaslavsky AM; Gelber RD
    Stat Med; 2005 Aug; 24(15):2317-34. PubMed ID: 15977292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A cost--utility analysis of treatment options for inguinal hernia in 1,513,008 adult patients.
    Stylopoulos N; Gazelle GS; Rattner DW
    Surg Endosc; 2003 Feb; 17(2):180-9. PubMed ID: 12415334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal drug pricing, limited use conditions and stratified net benefits for Markov models of disease progression.
    Zaric GS
    Health Econ; 2008 Nov; 17(11):1277-94. PubMed ID: 18186544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pertussis in adolescents and adults: should we vaccinate?
    Lee GM; Lebaron C; Murphy TV; Lett S; Schauer S; Lieu TA
    Pediatrics; 2005 Jun; 115(6):1675-84. PubMed ID: 15930232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is antibiotic prophylaxis for bacterial endocarditis cost-effective?
    Agha Z; Lofgren RP; VanRuiswyk JV
    Med Decis Making; 2005; 25(3):308-20. PubMed ID: 15951458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling animals' behavioral response by Markov chain models for capture-recapture experiments.
    Yang HC; Chao A
    Biometrics; 2005 Dec; 61(4):1010-7. PubMed ID: 16401274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An evaluation of the economic costs and patient-related consequences of treatments for benign prostatic hyperplasia.
    DiSantostefano RL; Biddle AK; Lavelle JP
    BJU Int; 2006 May; 97(5):1007-16. PubMed ID: 16542339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.